NASDAQ:GNFT Genfit (GNFT) Stock Price, News & Analysis $4.15 -0.04 (-0.95%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$3.89▼$4.2450-Day Range$3.89▼$4.6452-Week Range$2.89▼$6.05Volume7,451 shsAverage Volume16,513 shsMarket Capitalization$207.11 millionP/E RatioN/ADividend YieldN/APrice Target$13.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Genfit alerts: Email Address Genfit MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside213.3% Upside$13.00 Price TargetShort InterestHealthy0.12% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom $0.56 to ($0.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.04 out of 5 starsMedical Sector757th out of 910 stocksBiological Products, Except Diagnostic Industry128th out of 155 stocks 3.5 Analyst's Opinion Consensus RatingGenfit has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageGenfit has only been the subject of 1 research reports in the past 90 days.Read more about Genfit's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.12% of the float of Genfit has been sold short.Short Interest Ratio / Days to CoverGenfit has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Genfit has recently decreased by 3.38%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldGenfit does not currently pay a dividend.Dividend GrowthGenfit does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GNFT. Previous Next 0.6 News and Social Media Coverage Search Interest1 people have searched for GNFT on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genfit insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.20% of the stock of Genfit is held by insiders.Percentage Held by InstitutionsOnly 2.24% of the stock of Genfit is held by institutions.Read more about Genfit's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Genfit are expected to decrease in the coming year, from $0.56 to ($0.52) per share.Price to Book Value per Share RatioGenfit has a P/B Ratio of 2.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << About Genfit Stock (NASDAQ:GNFT)Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Read More GNFT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GNFT Stock News HeadlinesAugust 16, 2024 | finance.yahoo.comGenfit S.A. (GNFTF)August 6, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Rise in Tuesday TradingSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.July 27, 2024 | finanznachrichten.deGENFIT S.A.: Positive Opinion from EMA Committee for Ipsen's Iqirvo (elafibranor) in Primary Biliary CholangitisJuly 26, 2024 | globenewswire.comGENFIT: Positive Opinion from EMA Committee for Ipsen's Iqirvo® (elafibranor) in Primary Biliary CholangitisJuly 9, 2024 | globenewswire.comGENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et CommercialJune 17, 2024 | globenewswire.comGENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASHJune 10, 2024 | globenewswire.comGENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo® for Primary Biliary CholangitisSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.June 10, 2024 | reuters.comUS FDA approves Genfit and Ipsen's liver disease drugMay 29, 2024 | globenewswire.comGENFIT to Present Latest ACLF Research at EASL Congress™ 2024May 22, 2024 | globenewswire.comGENFIT: May 22, 2024 Combined Shareholders Meeting ResultsMay 15, 2024 | finanznachrichten.deGENFIT S.A.: GENFIT Reports First Quarter 2024 Financial InformationMay 14, 2024 | globenewswire.comGENFIT Reports First Quarter 2024 Financial InformationApril 25, 2024 | globenewswire.comGENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)April 15, 2024 | globenewswire.comGENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory DocumentsApril 5, 2024 | globenewswire.comGENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-FApril 5, 2024 | finanznachrichten.deGENFIT S.A.: GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate UpdateSee More Headlines Receive GNFT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GNFT CUSIPN/A CIK1757064 Webwww.genfit.com Phone(332) 016-4000FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Stock Price Target$13.00 High Stock Price Target$13.00 Low Stock Price Target$13.00 Potential Upside/Downside+213.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.92 Current Ratio2.94 Quick Ratio2.94 Sales & Book Value Annual Sales$28.57 million Price / Sales7.25 Cash FlowN/A Price / Cash FlowN/A Book Value$1.48 per share Price / Book2.80Miscellaneous Outstanding Shares49,906,000Free Float47,810,000Market Cap$207.11 million OptionableNot Optionable Beta1.22 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Jean-Francois Mouney (Age 69)Co-Founder & Chairman of the Board Comp: $389.42kMr. M. Pascal Prigent (Age 55)Chief Executive Officer Comp: $604.89kProf. Bart Staels (Age 61)Co-Founder & Chairman of the Scientific Advisory Board Mr. Thomas Baetz (Age 49)Chief Financial Officer Mr. Pascal Caisey (Age 55)Chief Operating Officer Dr. Meriam Kabbaj Ph.D. (Age 50)Chief Technology Officer Dr. Dean W. Hum Ph.D. (Age 62)Chief Scientific Officer Comp: $770.91kMr. Jean-Christophe Marcoux (Age 46)Chief Corporate Affairs Officer, Head of Investor Relations & Head of ESG Mr. Laurent Lannoo (Age 53)Corporate Secretary & Director of Legal Affairs Ms. Stefanie Magner J.D. (Age 42)Chief Compliance Officer & Executive VP of International Legal Affairs More ExecutivesKey CompetitorsPhibro Animal HealthNASDAQ:PAHCDianthus TherapeuticsNASDAQ:DNTH4D Molecular TherapeuticsNASDAQ:FDMTABIVAX Société AnonymeNASDAQ:ABVXPliant TherapeuticsNASDAQ:PLRXView All Competitors GNFT Stock Analysis - Frequently Asked Questions How have GNFT shares performed this year? Genfit's stock was trading at $3.85 at the beginning of the year. Since then, GNFT stock has increased by 7.8% and is now trading at $4.15. View the best growth stocks for 2024 here. What is Jean-François Mouney's approval rating as Genfit's CEO? 3 employees have rated Genfit Chief Executive Officer Jean-François Mouney on Glassdoor.com. Jean-François Mouney has an approval rating of 29% among the company's employees. This puts Jean-François Mouney in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. When did Genfit IPO? Genfit (GNFT) raised $132 million in an initial public offering (IPO) on Wednesday, March 27th 2019. The company issued 5,000,000 shares at a price of $26.33 per share. SVB Leerink and Barclays acted as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers. How do I buy shares of Genfit? Shares of GNFT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Genfit own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genfit investors own include Intercept Pharmaceuticals (ICPT), InterDigital (IDCC), STAG Industrial (STAG), Gilead Sciences (GILD), Occidental Petroleum (OXY), Vaxart (VXRT) and Exxon Mobil (XOM). This page (NASDAQ:GNFT) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genfit S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genfit With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.